Moderna mentioned Monday a smaller dosage of its Covid-19 vaccine is secure and generates a strong immune response in a research of youngsters ages 6 to 11.
Two 50 micrograms of the shot, half the dosage that's given to adults, produced antibody ranges that have been 1.5 occasions larger than these seen in younger adults, the corporate mentioned in a press launch, citing early knowledge from a section 2/3 trial.
The pictures have been additionally secure and usually well-tolerated in younger children; the commonest unintended effects have been fatigue, headache, fever, and injection web site ache, in accordance to the corporate. The vaccine was examined on greater than 4,700 kids.
Moderna says it plans to submit the info to the Food and Drug Administration, European Medicines Agency and different well being regulators in the "near term."
"We look forward to filing with regulators globally and remain committed to doing our part to help end the COVID-19 pandemic with a vaccine for adults and children of all ages," Moderna CEO Stephane Bancel mentioned in a press release.
The new knowledge comes a day earlier than a key FDA advisory committee meets to talk about whether or not to suggest Pfizer and BioNTech's vaccine for teenagers ages 5 to 11. The FDA might authorize the pictures inside days of the assembly, adopted by the Centers for Disease Control and Prevention subsequent week.
FDA workers mentioned late Friday that Pfizer's vaccine seems extremely efficient at stopping symptomatic infections in elementary college kids.
Many dad and mom say they’re anxious to get their kids vaccinated as children have began the brand new college yr with the delta variant nonetheless surging throughout America. The variety of new Covid circumstances in children stays exceptionally excessive, with greater than 1.1 million baby circumstances added over the previous six weeks, in accordance to the American Academy of Pediatrics.
based mostly on web site supplies www.cnbc.com